Affimed Stock Forecast, Price & News

Affimed (NASDAQ:AFMD) Frequently Asked Questions

Is Affimed a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Affimed in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Affimed stock.
View analyst ratings for Affimed or view top-rated stocks.

How has Affimed's stock price been impacted by COVID-19 (Coronavirus)?

Affimed's stock was trading at $1.82 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AFMD shares have increased by 275.3% and is now trading at $6.83.
View which stocks have been most impacted by COVID-19.

Are investors shorting Affimed?

Affimed saw a decline in short interest in the month of November. As of November 15th, there was short interest totaling 2,870,000 shares, a decline of 24.7% from the October 31st total of 3,810,000 shares. Based on an average daily volume of 1,550,000 shares, the days-to-cover ratio is presently 1.9 days. Approximately 2.6% of the shares of the stock are sold short.
View Affimed's Short Interest.

When is Affimed's next earnings date?

Affimed is scheduled to release its next quarterly earnings announcement on Thursday, April 21st 2022.
View our earnings forecast for Affimed.

How were Affimed's earnings last quarter?

Affimed (NASDAQ:AFMD) announced its quarterly earnings results on Wednesday, November, 10th. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.13) by $0.01. The biopharmaceutical company had revenue of $10.21 million for the quarter, compared to analyst estimates of $11.79 million. Affimed had a negative trailing twelve-month return on equity of 40.23% and a negative net margin of 132.18%. During the same quarter in the prior year, the firm earned ($0.08) earnings per share.
View Affimed's earnings history.

What price target have analysts set for AFMD?

8 Wall Street analysts have issued 1 year target prices for Affimed's stock. Their forecasts range from $10.00 to $15.00. On average, they anticipate Affimed's stock price to reach $12.71 in the next twelve months. This suggests a possible upside of 86.2% from the stock's current price.
View analysts' price targets for Affimed or view top-rated stocks among Wall Street analysts.

Who are Affimed's key executives?

Affimed's management team includes the following people:

• Adolf Hoess, Chief Executive Officer
• Wolfgang Fischer, Chief Operating Officer
• Angus W. Smith, Chief Financial Officer
• Andreas Harstrick, Chief Medical Officer
• Arndt Schottelius, Chief Scientific Officer

Who are some of Affimed's key competitors?

Some companies that are related to Affimed include Aurinia Pharmaceuticals (AUPH), Pacira BioSciences (PCRX), Ligand Pharmaceuticals (LGND), ChemoCentryx (CCXI), TG Therapeutics (TGTX), Lyell Immunopharma (LYEL), Sage Therapeutics (SAGE), Nektar Therapeutics (NKTR), Harmony Biosciences (HRMY), Prothena (PRTA), Emergent BioSolutions (EBS), Indivior (INVVY), Turning Point Therapeutics (TPTX), Corcept Therapeutics (CORT) and Xencor (XNCR).
View all of AFMD's competitors.

What other stocks do shareholders of Affimed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Affimed investors own include Novavax (NVAX), JetBlue Airways (JBLU), SentinelOne (S), American International Group (AIG), Sorrento Therapeutics (SRNE), Catalyst Pharmaceuticals (CPRX), Amarin (AMRN), Rigel Pharmaceuticals (RIGL), Viking Therapeutics (VKTX) and Lipocine (LPCN).

What is Affimed's stock symbol?

Affimed trades on the NASDAQ under the ticker symbol "AFMD."

Who are Affimed's major shareholders?

Affimed's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.90%), Point72 Asset Management L.P. (6.23%), 683 Capital Management LLC (5.70%), Granahan Investment Management Inc. MA (3.44%), Goldman Sachs Group Inc. (2.90%) and Janus Henderson Group PLC (1.21%).

Which institutional investors are selling Affimed stock?

AFMD stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Granahan Investment Management Inc. MA, Millennium Management LLC, Russell Investments Group Ltd., Two Sigma Advisers LP, Squarepoint Ops LLC, Sphera Funds Management LTD., and M&G Investment Management Ltd..

Which institutional investors are buying Affimed stock?

AFMD stock was acquired by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Point72 Asset Management L.P., Janus Henderson Group PLC, Altium Capital Management LP, Arrowstreet Capital Limited Partnership, 683 Capital Management LLC, Stonepine Capital Management LLC, and Connor Clark & Lunn Investment Management Ltd..

How do I buy shares of Affimed?

Shares of AFMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Affimed's stock price today?

One share of AFMD stock can currently be purchased for approximately $6.83.

How much money does Affimed make?

Affimed has a market capitalization of $671.30 million and generates $32.39 million in revenue each year. The biopharmaceutical company earns $-47.25 million in net income (profit) each year or ($0.55) on an earnings per share basis.

How many employees does Affimed have?

Affimed employs 158 workers across the globe.

What is Affimed's official website?

The official website for Affimed is www.affimed.com.

Where are Affimed's headquarters?

Affimed is headquartered at TECHNOLOGIEPARK IM NEUENHEIMER FELD 582, HEIDELBERG 2M, 69120.

How can I contact Affimed?

Affimed's mailing address is TECHNOLOGIEPARK IM NEUENHEIMER FELD 582, HEIDELBERG 2M, 69120. The biopharmaceutical company can be reached via phone at 496221674360, via email at [email protected], or via fax at 49-6221-653-0777.